Advances in research and current challenges in the treatment of advanced HER2-low breast cancer

被引：0

作者：

Qin, Qiang ^{[1
]}

机构：

[1] Nanning Maternal & Child Hlth Hosp, Breast & Thyroid Surg Dept, Nanning, Peoples R China

来源：

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2025年 / 13卷

关键词：

breast cancer; HER2-low expression; T-DXd therapy; treatment; HER2-targeted therapies; ANTIBODY-DRUG CONJUGATE; TRASTUZUMAB DERUXTECAN; OPEN-LABEL; EMTANSINE; AMPLIFICATION; PERTUZUMAB; EXPRESSION; INHIBITOR; EFFICACY; DS-8201A;

D O I：

10.3389/fcell.2025.1451471

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Human epidermal growth factor receptor 2 (HER2)-low breast cancer is defined as breast cancer with an immunohistochemistry (IHC) score of 1+ or 2+ and in situ hybridisation (ISH)-negative. The traditional HER2 classification (negative or positive) has limitations, with only 15%-20% of the breast cancer population being positive and suitable for HER2-targeted therapy. The new clinical study, DESTINY-Breast04, shows that trastuzumab deruxtecan (T-DXd) has a significant effect on advanced HER2-low breast cancers, a classification that accounts for approximately half of the advanced breast cancer population. However, the detection methods and evaluation criteria for HER2-low breast cancer have not yet been standardised, and the toxicity and resistance mechanisms associated with T-DXd therapy are still unclear. This article focuses on these issues and describes the progress and challenges of T-DXd-related therapy in the treatment of advanced breast cancer patients with low HER2 expression.

引用

页数：8

共 53 条

[1] Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan [J].

Ali, Azka ;

Graff, Stephanie L. .

CURRENT ONCOLOGY REPORTS, 2024, 26 (01) :1-9

[2] FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer [J].

Amiri-Kordestani, Laleh ;

Blumenthal, Gideon M. ;

Xu, Qiang Casey ;

Zhang, Lijun ;

Tang, Shenghui W. ;

Ha, Linan ;

Weinberg, Wendy C. ;

Chi, Bo ;

Candau-Chacon, Reyes ;

Hughes, Patricia ;

Russell, Anne M. ;

Miksinski, Sarah Pope ;

Chen, Xiao Hong ;

McGuinn, W. David ;

Palmby, Todd ;

Schrieber, Sarah J. ;

Liu, Qi ;

Wang, Jian ;

Song, Pengfei ;

Mehrotra, Nitin ;

Skarupa, Lisa ;

Clouse, Kathleen ;

Al-Hakim, Ali ;

Sridhara, Rajeshwari ;

Ibrahim, Amna ;

Justice, Robert ;

Pazdur, Richard ;

Cortazar, Patricia .

CLINICAL CANCER RESEARCH, 2014, 20 (17) :4436-4441

[3]

Bergh J, 2021, LANCET ONCOL, V22, P1139, DOI 10.1016/S1470-2045(21)00288-6

[4] Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy [J].

Burris, Howard A., III ;

Rugo, Hope S. ;

Vukelja, Svetislava J. ;

Vogel, Charles L. ;

Borson, Rachel A. ;

Limentani, Steven ;

Tan-Chiu, Elizabeth ;

Krop, Ian E. ;

Michaelson, Richard A. ;

Girish, Sandhya ;

Amler, Lukas ;

Zheng, Maoxia ;

Chu, Yu-Waye ;

Klencke, Barbara ;

O'Shaughnessy, Joyce A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) :398-405

[5] 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J].

Cameron, David ;

Piccart-Gebhart, Martine J. ;

Gelber, Richard D. ;

Procter, Marion ;

Goldhirsch, Aron ;

de Azambuja, Evandro ;

Castro, Gilberto, Jr. ;

Untch, Michael ;

Smith, Ian ;

Gianni, Luca ;

Baselga, Jose ;

Al-Sakaff, Nedal ;

Lauer, Sabine ;

McFadden, Eleanor ;

Leyland-Jones, Brian ;

Bell, Richard ;

Dowsett, Mitch ;

Jackisch, Christian .

LANCET, 2017, 389 (10075) :1195-1205

[6] Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer [J].

Chick, R. Connor ;

Clifton, G. Travis ;

Hale, Diane F. ;

Vreeland, Timothy J. ;

Hickerson, Annelies T. ;

Bohan, Phillip M. Kemp ;

McCarthy, Patrick M. ;

Litton, Jennifer K. ;

Alatrash, Gheath ;

Murthy, Rashmi K. ;

Qiao, Na ;

Philips, Anne ;

Lukas, Jason ;

Holmes, Jarrod P. ;

Mittendorf, Elizabeth A. ;

Peoples, George E. .

CLINICAL IMMUNOLOGY, 2021, 225

[7] Acquired Resistance to Antibody-Drug Conjugates [J].

Collins, Denis M. ;

Bossenmaier, Birgit ;

Kollmorgen, Gwendlyn ;

Niederfellner, Gerhard .

CANCERS, 2019, 11 (03)

[8]

Cooke T, 2001, Ann Oncol, V12 Suppl 1, pS23

[9] Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer [J].

Cortes, J. ;

Kim, S. -B ;

Chung, W. -P ;

Im, S. -A ;

Park, Y. H. ;

Hegg, R. ;

Kim, M. H. ;

Tseng, L. -M ;

Petry, V ;

Chung, C. -F ;

Iwata, H. ;

Hamilton, E. ;

Curigliano, G. ;

Xu, B. ;

Huang, C. -S ;

Kim, J. H. ;

Chiu, J. W. Y. ;

Pedrini, J. L. ;

Lee, C. ;

Liu, Y. ;

Cathcart, J. ;

Bako, E. ;

Verma, S. ;

Hurvitz, S. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12) :1143-1154

[10] Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06) [J].

Curigliano, Giuseppe ;

Hu, Xichun ;

Dent, Rebecca Alexandra ;

Yonemori, Kan ;

Barrios Sr, Carlos H. ;

O'Shaughnessy, Joyce ;

Wildiers, Hans ;

Zhang, Qingyuan ;

Im, Seock-Ah ;

Saura, Cristina ;

Biganzoli, Laura ;

Sohn, Joohyuk ;

Levy, Christelle ;

Jacot, William ;

Begbie, Natasha ;

Ke, Jun ;

Patel, Gargi Surendra ;

Bardia, Aditya .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) :LBA1000-LBA1000

← 1 2 3 4 5 6 →